Literature DB >> 18420505

Pharmaceutical promotion to physicians and First Amendment rights.

Aaron S Kesselheim1, Jerry Avorn.   

Abstract

Mesh:

Year:  2008        PMID: 18420505     DOI: 10.1056/NEJMsb0708920

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Science, medicine and industry: are we getting out of the black hole in sepsis research?

Authors:  Peter M Suter; Jukka Takala
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

2.  Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines.

Authors:  Kristina Klara; Jeanie Kim; Joseph S Ross
Journal:  J Gen Intern Med       Date:  2018-02-26       Impact factor: 5.128

3.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

4.  Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.

Authors:  Aaron S Kesselheim; Michelle M Mello; David M Studdert
Journal:  PLoS Med       Date:  2011-04-05       Impact factor: 11.069

5.  Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs.

Authors:  George A Chressanthis; Pratap Khedkar; Nitin Jain; Prashant Poddar; Michael G Seiders
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-21       Impact factor: 2.885

6.  Pharmaceutical Sales Representatives in the United States and China: The Need for Professional Public Space.

Authors:  Xiaoying Chen
Journal:  Health Care Anal       Date:  2021-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.